DrugPatentWatch Database Preview
Tasimelteon - Generic Drug Details
What are the generic drug sources for tasimelteon and what is the scope of patent protection?
Tasimelteon
is the generic ingredient in one branded drug marketed by Vanda Pharms Inc and is included in one NDA. There are eleven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Tasimelteon has one hundred and twenty-nine patent family members in thirty-one countries.
There are three drug master file entries for tasimelteon. One supplier is listed for this compound.
Summary for tasimelteon
| International Patents: | 129 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 3 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 43 |
| Clinical Trials: | 17 |
| Patent Applications: | 55 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for tasimelteon |
| DailyMed Link: | tasimelteon at DailyMed |
Recent Clinical Trials for tasimelteon
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Saint-Joseph University | Phase 3 |
| Vanda Pharmaceuticals | Phase 2 |
| Vanda Pharmaceuticals | Phase 4 |
Recent Litigation for tasimelteon
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. | 2020-01-22 |
| Vanda Pharmaceuticals Inc. v. Apotex Inc. | 2020-01-21 |
| Vanda Pharmaceuticals Inc. v. Apotex Inc. | 2019-12-30 |
Pharmacology for tasimelteon
| Drug Class | Melatonin Receptor Agonist |
| Mechanism of Action | Melatonin Receptor Agonists |
Synonyms for tasimelteon
| (-)-(trans)-N-[[2-(2,3-Dihydrobenzofuran-4-yl)cycloprop-1-yl] methyl]propanamide |
| (trans)-N-[[2-(2,3-dihydrobenzofuran-4-yl) cyclopropyl]methyl]propanamide |
| (trans)-N-[[2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl]methyl]propanamide |
| 609799-22-6 |
| 799T226 |
| AC-6143 |
| ACT06729 |
| AK188029 |
| AKOS025149360 |
| AS-35291 |
| BCP07180 |
| BMS 214778 |
| BMS-214,778 |
| BMS-214778 |
| CHEBI:79042 |
| CHEMBL2103822 |
| CS-5512 |
| D09388 |
| DB09071 |
| DTXSID70209826 |
| EX-A2729 |
| GTPL7393 |
| Hetlioz |
| Hetlioz (TN) |
| HY-14803 |
| J3.640.465E |
| KS-0000063S |
| N-(((1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide |
| N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)propionamide |
| N-([(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide |
| N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide |
| N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide |
| Propanamide, N-(((1R,2R)-2-(2,3-dihydro-4-benzofuranyl)cyclopropyl)methyl)- |
| PTOIAAWZLUQTIO-GXFFZTMASA-N |
| Q7687250 |
| s4281 |
| SB16782 |
| SCHEMBL3505912 |
| SHS4PU80D9 |
| Tasimelteon (USAN/INN) |
| Tasimelteon [USAN:INN] |
| Tasimelteon, >=98% (HPLC) |
| tasimelteonum |
| UNII-SHS4PU80D9 |
| VEC 162 |
| VEC-162 |
| X5820 |
| ZINC4392649 |
Paragraph IV (Patent) Challenges for TASIMELTEON
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| HETLIOZ | CAPSULE;ORAL | tasimelteon | 205677 | 2018-01-31 |
US Patents and Regulatory Information for tasimelteon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for tasimelteon
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2016204178 | Start Trial |
| South Korea | 20190006598 | Start Trial |
| Mexico | 2016009231 | Start Trial |
| Russian Federation | 2014134555 | Start Trial |
| China | 1239886 | Start Trial |
| Chile | 2014001993 | Start Trial |
| Japan | 6267260 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
